Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Scancell Holdings, a developer of therapeutic cancer vaccines, has received approval for its proposal to conduct a Phase I clinical trial on SCIB1 in the UK, by the Gene Therapy Advisory Committee (GTAC) and by Medicines and Healthcare products Regulatory Agency (MHRA) Medicines Division.
Subscribe to our email newsletter
Scancell said that SCIB1 is a new DNA ImmunoBody vaccine being developed using its patented ImmunoBody technology for the treatment of melanoma.
In addition, Scancell’s US partner Ichor Medical Systems (Ichor) has obtained the required parallel approval from the MHRA Devices Division for the use of Ichor’s TriGrid electroporation delivery device to administer SCIB1 to patients participating in the trial of SCIB1.
Reportedly, the patient enrollment for the Phase I clinical trial of SCIB1 is expected to commence shortly at three UK hospital centres in Nottingham, Manchester and Newcastle.
Scancell is confident that TriGrid will provide a delivery system for its SCIB1 melanoma vaccine as it enters clinical trials.
David Evans, chairman of Scancell, said: “With the approvals from GTAC and MHRA in place Scancell is expected to commence the Phase I clinical trial of our first therapeutic cancer vaccine SCIB1 during this second quarter which is exactly on track with our programme.”